Cardiogenic Shock
Conditions
Keywords
Acute decompensated heart failure, cardiogenic shock, intra-aortic balloon pump
Brief summary
The aim of the study is to demonstrate the superiority of early intra-aortic balloon pump implantation at admission over local clinical practice (pharmacological only) in acute decompensated heart failure patients with cardiogenic shock, with respect to 60-day survival or successful bridge to heart replacement therapies (heart transplant or Left Ventricular Assist Device implantation).
Detailed description
Cardiogenic shock (CS) is the most severe form of acute heart failure, with in-hospital mortality up to 50%. Failure to improve mortality has been reported, despite observed improvements in hemodynamics. Previous studies on CS have almost exclusively been focused on CS following an acute coronary syndrome (ACS). Chronic heart failure patients with acute decompensation (ADHF) and CS represent a unique physiologic phenotype compared with ACS patients, which may lead to a differential response to device therapy. Recent evidences emphasize that intra-aortic balloon pump (IABP) is not recommended for patients with ACS-related CS, but it is associated with a high likelihood of bridge to durable Left Ventricular Assist Device or heart transplant without the need for escalation to more potent temporary mechanical circulatory support devices, when implanted in ADHF patients. Data retrieved from the available literature in the setting of patients with CS not related to ACS are poor even in large, well-reported registries. Accordingly, Altshock-2 trial has been designed to test the superiority of early IABP implantation at admission over local clinical practice (pharmacological only) in ADHF patients with CS, with respect to 60-day survival or successful bridge to heart replacement therapies
Interventions
COMBINATION_PRODUCTEarly intra-aortic balloon pump (IABP) implantation
IABP implantation within 6 hours since cardiogenic shock symptoms onset
OTHERStandard of care as vasoactive agent
Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
Sponsors
Niguarda Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open
Intervention model description
Multicentre Prospective Controlled Randomized Trial in patients with ADHF complicated by CS. Patients will be randomized 1:1 to early IABP versus standard of care. Early IABP will be defined as IABP implantation for CS patients within 6 hours since CS symptoms onset.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 and \< 75, men and women; * need of vasoactive agents to maintain SBP \> 90 mmHg or MAP \> 60 mmHg. * Left ventricle systolic function ≤35% * SCAI B-D according to CSWG definition (JACC 2022)
Exclusion criteria
* septic shock with evident septic focus; * severe peripheral vascular disease * CS secondary to cardiac and non-cardiac surgery; * Acute myocardial infarction within 1 month; * Suspected or documented myocarditis * Pulmonary embolism * Chronic end-stage organ dysfunction that would preclude heart transplant/durable VAD * ominous prognosis (life expectancy \< 1 year); * any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial * pregnant, lactating or women planning pregnancy during the course of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful bridge to heart replacement therapies, namely heart transplantation or left ventricular assist device implantation | 60 days | Number of participants to heart transplant or Left Ventricular Assist Device implantation |
| Survival | 60 days | Rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum duration of inotropic/vasopressor therapy among the two groups | Through study completion, an avererage of 30 days | To compare maximum duration of inotropic/vasopressor therapy among the two groups (early IABP vs standard) |
| Renal replacement therapy, namely any need of replacement of kidney function due to renal failure by means of the following techniques: continuous hemofiltration and hemodialysis, intermittent hemodialysis, and peritoneal dialysis | 60 days | Number of participants who need a renal replacement therapy among the two groups (early IABP vs standard) |
| early IABP vs standard | 60 days | To compare 60-day overall survival among the two groups |
| Maximum sequential organ failure assessment (SOFA) | Through study completion, an avererage of 30 days | To compare maximum sequential organ failure assessment (SOFA) |
| Maximum inotropic score among the two groups | Through study completion, an avererage of 30 days | To compare maximum inotropic score among the two groups (early IABP vs standard). IS (mcg/kg/min) = \[dopamine, dobutamine + 100 x (norepinephrine+epinephrine) +15 x IPDE-3 +10for levosimendan\] (Reference: Int J Artif Organs. 2016 Feb;39(2):94-7) |
Countries
Italy
Outcome results
None listed